Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 3;3(2):169-174.
doi: 10.21873/cdp.10197. eCollection 2023 Mar-Apr.

DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma

Affiliations
Review

DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma

Georgios I Metaxas et al. Cancer Diagn Progn. .

Abstract

DNA mismatch repair system (MMR) is considered a leading genetic mechanism in stabilizing DNA structure and maintaining its function. DNA MMR is a highly conserved system in bacteria, prokaryotic, and eukaryotic cells, and provides the highest protection to DNA by repairing micro-structural alterations. DNA MMR proteins are involved in the detection and repair of intra-nucleotide base-to-base errors inside the complementary DNA strand recognizing the recently synthesized strand from the parental template. During DNA replication, a spectrum of errors including base insertion, deletion, and miss-incorporation negatively affect the molecule's structure and its functional stability. A broad spectrum of genomic alterations such as promoter hyper methylation, mutation, and loss of heterozygosity (LOH) in MMR genes including predominantly hMLH1, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2 lead to their loss of base-to-base error repairing procedure. Microsatellite instability (MSI) refers to the DNA MMR gene alterations that are observed in a variety of malignancies of different histological origins. In the current review, we present the role of DNA MMR deficiency in breast adenocarcinoma, a leading cancer-based cause of death in females worldwide.

Keywords: Breast; MMR; adenocarcinoma; epigenetics; methylation; review.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to declare in relation to this study.

Similar articles

Cited by

References

    1. Ma F, Laster K, Dong Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun. 2022;13(1):5651. doi: 10.1038/s41467-022-33351-4. - DOI - PMC - PubMed
    1. Tasli F, Cavdar D, Kececi SD, Zengel B, Adibelli ZH, Dal G, Gonen I, Oz O, Yilmaz C, Ozdemir O, Mollamehmetoglu H, Dilek I, Ilhan E, Uslu A. The importance of the pathological perspective in the management of the invasive lobular carcinoma. Breast J. 2022;2022:2461242. doi: 10.1155/2022/2461242. - DOI - PMC - PubMed
    1. Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A, El Kadmiri N. Risk factors for breast cancer in women: an update review. Med Oncol. 2022;39(12):197. doi: 10.1007/s12032-022-01804-x. - DOI - PubMed
    1. Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, Miller C, Brown M, Han J, Adeboyeje G. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308–316. doi: 10.1002/em.22505. - DOI - PubMed
    1. Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Genomic classification of HER2-positive patients with 80-gene and 70-gene signatures identifies diversity in clinical outcomes with HER2-targeted neoadjuvant therapy. JCO Precis Oncol. 2022;6:e2200197. doi: 10.1200/PO.22.00197. - DOI - PMC - PubMed

LinkOut - more resources